CANY
VRDN icon

Caxton Associates (New York)’s Viridian Therapeutics VRDN Stock Holding History

Caxton Associates (New York)’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,974
Closed -$525K – 647
2022
Q4 		$525K Buy
+17,974
New +$414K 0.04% 226

Other funds holding VRDN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Caxton Associates (New York)'s VRDN Position: Q1 2023 in Review

Caxton Associates (New York) sold out of Viridian Therapeutics (VRDN) in Q1 2023, closing a stake of 17,974 shares — an estimated $525K sold.

Caxton Associates (New York) first reported a position in VRDN in Q4 2022 and held it in 1 quarter. The position peaked at $525K in Q4 2022. 135 funds tracked by Wall St. Rank hold VRDN as of Q1 2023.

  • Caxton Associates (New York) reported no remaining Viridian Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 17,974 Viridian Therapeutics shares in Q1 2023, an estimated $525K.
  • Caxton Associates (New York) first reported a position in Viridian Therapeutics in Q4 2022 and held it in 1 quarter.
  • Caxton Associates (New York)'s Viridian Therapeutics position peaked at $525K in Q4 2022.
  • 135 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.